AWAndrea Wang-Gillam

Andrea Wang-Gillam

*This is an algorithmically generated author record based on publicly available information.

Andrea Wang-Gillam has a total of 75 co-authors. Here are the top co-authors by number of shared publications:

  • Kian-Huat Lim

    Division of Oncology, Department of Internal Medicine, Washington University School of Medicine, St. Louis, USA

    4 shared publications
  • Feng Gao

    Department of Surgery, Washington University School of Medicine, Saint Louis, MO, USA

    3 shared publications
  • David Linehan

    Department of Surgery, Washington University in St. Louis, St. Louis, Missouri, United States of America

    2 shared publications
  • Dengfeng Cao

    Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA

    2 shared publications
  • Lin Li

    Division of Oncology, Department of Internal Medicine, Washington University School of Medicine, Saint Louis, Missouri

    2 shared publications
  • Mai Xu

    Division of Oncology, Department of Internal Medicine, Washington University School of Medicine, Saint Louis, Missouri

    2 shared publications

Latest Publications

  • Open Access

    TPL2 enforces RAS-induced inflammatory signaling and is activated by point mutations

    by Paarth B. Dodhiawala, Namrata Khurana, Daoxiang Zhang, Yi Cheng, Lin Li, Qing Wei, Kuljeet Seehra, Hongmei Jiang, Patrick M. Grierson, Andrea Wang-Gillam, et al.

    NF-κB transcription factors, driven by the IRAK/IKK cascade, confer treatment resistance in pancreatic ductal adenocarcinoma (PDAC), a cancer characterized by near-universal KRAS mutation. Through reverse-phase protein array and RNA sequencing we discovered that IRAK4 also contributes substantially to MAPK activation in KRAS-mutant PDAC. IRAK4 ablation completely blocked RAS-induced transformation of human and murine cells. Mechanistically, expression of mutant KRAS stimulated an inflammatory, autocrine IL-1β signaling loop that activated IRAK4 and the MAPK pathway. Downstream of IRAK4, we uncovered TPL2 (also known as MAP3K8 or COT) as the essential kinase that propels both MAPK and NF-κB cascades. Inhibition of TPL2 blocked both MAPK and NF-κB signaling, and suppressed KRAS-mutant cell growth. To counter chemotherapy-induced genotoxic stress, PDAC cells upregulated TLR9, which activated prosurvival IRAK4/TPL2 signaling. Accordingly, a TPL2 inhibitor synergized with chemotherapy to curb PDAC growth in vivo. Finally, from TCGA we characterized 2 MAP3K8 point mutations that hyperactivate MAPK and NF-κB cascades by impeding TPL2 protein degradation. Cancer cell lines naturally harboring these MAP3K8 mutations are strikingly sensitive to TPL2 inhibition, underscoring the need to identify these potentially targetable mutations in patients. Overall, our study establishes TPL2 as a promising therapeutic target in RAS- and MAP3K8-mutant cancers and strongly prompts development of TPL2 inhibitors for preclinical and clinical studies.


  • Open Access

    Liposomal Irinotecan + 5-FU/LV in Metastatic Pancreatic Cancer

    by Teresa Macarulla Mercadé, Li-Tzong Chen, Chung-Pin Li, Jens T. Siveke, David Cunningham, György Bodoky, Jean-Frédéric Blanc, Kyung-Hun Lee, Andrew Dean, Bruce Belanger, et al.

    Objectives: The NAnoliPOsomaL Irinotecan (NAPOLI-1) study (NCT01494506) was the largest global phase 3 study in a post-gemcitabine metastatic pancreatic adenocarcinoma (mPAC) population (N = 417). The subanalyses reported here investigated the prognostic effect of tumor characteristics and disease stage, prior treatment characteristics, baseline patient characteristics on survival outcomes in NAPOLI-1, and whether liposomal irinotecan (nal-IRI) + 5-fluorouracil/leucovorin (5-FU/LV) benefited patients with mPAC across subgroups. Methods: Post hoc analyses were performed in the NAPOLI-1 population (4 across tumor characteristics and disease stage, 6 across prior treatment characteristics, and 4 across patient baseline characteristics). Survival outcomes were estimated by Kaplan-Meier analysis and patient safety data were evaluated. Results: Mortality and morbidity risk was lower on nal-IRI+5-FU/LV treatment across subgroups. Exceptions were patients who had received prior nonliposomal irinotecan and those who had undergone prior Whipple procedure (overall survival hazard ratio = 1.25 and 1.23, respectively). Decreased appetite, liver metastases, and number of measurable metastatic lesions seemed to be prognostic of survival in this population. Subgroup safety data were generally comparable with those in the overall NAPOLI-1 safety population. Conclusions: A diverse population of patients with mPAC that progressed on gemcitabine-based therapy benefited from nal-IRI+5-FU/LV versus 5-FU/LV, potentially helping guide treatment decisions for challenging cases.


  • Concurrent HER or PI3K Inhibition Potentiates the Antitumor Effect of the ERK Inhibitor Ulixertinib in Preclinical Pancreatic Cancer Models

    by Hongmei Jiang, Mai Xu, Lin Li, Patrick Grierson, Paarth Dodhiawala, Maureen Highkin, Daoxiang Zhang, Qiong Li, Andrea Wang-Gillam, Kian-Huat Lim

    Effective treatment for pancreatic ductal adenocarcinoma (PDAC) is an urgent, unmet medical need. Targeting KRAS, the oncogene that is present in >95% of PDAC, is a heavily pursued strategy, but remains unsuccessful in the clinic. Therefore, targeting key effector cascades of KRAS oncoprotein, particularly the mitogenic RAF–MEK–ERK pathway, represents the next best strategy. However, RAF or MEK inhibitors have failed to show clinical efficacy in PDAC. Several studies have shown that cancer cells treated with RAF or MEK inhibitors adopt multiple mechanisms to reactivate ERK signaling. Therefore, development of ERK-specific inhibitors carries the promise to effectively abrogate this pathway. Ulixertinib (or BVD-523) is a first-in-class ERK-specific inhibitor that has demonstrated promising antitumor activity in a phase I clinical trial for advanced solid tumors with NRAS and BRAF mutations, providing a strong rationale to test this inhibitor in PDAC. In this study, we show that ulixertinib effectively inhibits in vitro growth of multiple PDAC lines and potentiates the cytotoxic effect of gemcitabine. Moreover, we found that PDAC cells treated with ulixertinib upregulates the parallel PI3K–AKT pathway through activating the HER/ErbB family proteins. Concurrent inhibition of PI3K or HER proteins synergizes with ulixertinib in suppressing PDAC cell growth in vitro and in vivo. Overall, our study provides the preclinical rationale for testing combinations of ulixertinib with chemotherapy or PI3K and HER inhibitors in PDAC patients. Mol Cancer Ther; 17(10); 2144–55. ©2018 AACR.


  • Open Access

    A clinically feasible multiplex proteomic immunoassay as a novel functional diagnostic for pancreatic ductal adenocarcinoma

    by Kian-Huat Lim, Emma Langley, Feng Gao, Jingqin Luo, Lin Li, Gary Meyer, Phillip Kim, Sharat Singh, Vladamir M. Kushnir, Dayna S. Early, et al.

    // <![CDATA[ $('.header-date').hide();$('#titleAuthors').hide();$('#abstractHeader').hide(); // ]]> Kian-Huat Lim1, Emma Langley5, Feng Gao4, Jingqin Luo4, Lin Li1, Gary Meyer5, Phillip Kim5, Sharat Singh5, Vladamir M. Kushnir2, Dayna S. Early2, Daniel K. Mullady2, Steven A. Edmundowicz6, Sachin Wani6, Faris M. Murad7, Dengfeng Cao3, Riad R. Azar2 and Andrea Wang-Gillam1 1 Division of Oncology, Department of Internal Medicine, Washington University School of Medicine, St. Louis, MO, USA 2 Division of Gastroenterology, Department of Internal Medicine, Washington University School of Medicine, St. Louis, MO, USA 3 Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA 4 Department of Surgery, Division of Public Health Sciences, Washington University School of Medicine, St. Louis, MO, USA 5 Prometheus Laboratories Inc., San Diego, CA, USA 6 Division of Gastroenterology and Hepatology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA 7 NorthShore University HealthSystem, Evanston, IL, USA Correspondence to: Andrea Wang-Gillam, email: // <![CDATA[ mail("awang","dom.wustl",14,"") // ]]> Keywords: pancreatic cancer, proteomics, fine-needle aspiration, signaling events, prognosis Received: January 28, 2017 Accepted: February 16, 2017 Published: February 23, 2017


  • Targeting RAS -mutant Cancers: Is ERK the Key?

    by Meagan B. Ryan, Channing J. Der, Andrea Wang-Gillam, Adrienne D. Cox


  • Perioperative Therapy for Surgically Resectable Pancreatic Adenocarcinoma

    by Lingling Du, Melissa DeFoe, Marianna B. Ruzinova, Jeffrey R. Olsen, Andrea Wang-Gillam


  • Open Access

    Advanced pancreatic adenocarcinoma: a review of current treatment strategies and developing therapies

    by Andrea Teague, Kian-Huat Lim, Andrea Wang-Gillam

    Pancreatic adenocarcinoma is one of the deadliest solid malignancies. A large proportion of patients are diagnosed with locally advanced or metastatic disease at the time of presentation and, unfortunately, this severely limits the number of patients who can undergo surgical resection, which offers the only chance for cure. Recent therapeutic advances for patients with advanced pancreatic cancer have extended overall survival, but prognosis still remains grim. Given that traditional chemotherapy is ineffective in curing advanced pancreatic adenocarcinoma, current research is taking a multidirectional approach in the hopes of developing more effective treatments. This article reviews the major clinical trial data that is the basis for the current chemotherapy regimens used as first- and second-line treatments for advanced pancreatic adenocarcinoma. We also review the current ongoing clinical trials, which include the use of agents targeting the oncogenic network signaling of K-Ras, agents targeting the extracellular matrix, and immune therapies.


  • Open Access

    Nab-paclitaxel monotherapy in refractory pancreatic adenocarcinoma

    by Parvin F. Peddi, May Cho, Jian Wang, Feng Gao, Andrea Wang-Gillam

    Nab-paclitaxel monotherapy in refractory pancreatic adenocarcinoma


  • Open Access

    Synergistic Effects of Concurrent Blockade of PI3K and MEK Pathways in Pancreatic Cancer Preclinical Models

    by Hua Zhong, Cesar Sanchez, Dirk Spitrzer, Stacy Plambeck-Suess, Jesse Gibbs, Williams G. Hawkins, David Denardo, Feng Gao, Robert A. Pufahl, Albert C. Lockhart, et al.

    Patients with pancreatic cancer have dismal prognoses, and novel therapies are urgently needed. Mutations of the KRAS oncogene occur frequently in pancreatic cancer and represent an attractive target. Direct targeting of the predominant KRAS pathways have been challenging and research into therapeutic strategies have been now refocused on pathways downstream of KRAS, phosphoinositide 3-kinase (PI3K) and mitogen-activated protein kinase (MAPK [MEK]). We hypothesized that concurrent inhibition of the PI3K and MEK pathways would result in synergistic antitumor activity, as it would circumvent the compensatory feedback loop between the two pathways. We investigated the combined effect of the PI3K inhibitor, GDC0941, and the MEK inhibitor, AZD6244, on cell viability, apoptosis and cell signaling in a panel of pancreatic cancer cell lines. An in vivo analysis was conducted on pancreatic cancer xenografts. While BxPC-3 (KRAS wild type) and MIA PaCa-2 (KRAS mutated) cell lines were sensitive to GDC0941 and AZD6244 as single agents, synergistic inhibition of tumor cell growth and induction of apoptosis were observed in both cell lines when the two drugs were combined. Interestingly, phosphorylation of the cap-dependent translational components, 4E-binding protein (p-4E-BP1) and S6 was found to be closely associated with sensitivity to GDC0941 and AZD6244. In BxPC-3 cell xenografts, survival differences were observed between the control and the AZD6244, GDC0941, and combination groups. Our study provides the rationale for concurrent targeting of the PI3K and MEK pathways, regardless of KRAS status, and suggests that phosphorylation of 4E-BP1and S6 can serve as a predictive biomarker for response to treatment.